SCHEMBL3549997

SCHEMBL3549997

COC(=O)N1CC=C(C(F)(F)F)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.37
TSHR P16473 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.34
PKM P14618 2/20 0.34
ABHD6 Q9BV23 2/20 0.34
SOS1 Q07889 1/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.33
KMT2A Q03164 2/20 0.33
LMNA P02545 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
THRB P10828 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
CFTR P13569 1/20 0.33
BLM P54132 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
CHRNB2 P17787 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5261649 0.83 ESR2 (0.43) MAPTESR2MAPK1SMN1; SMN2
SCHEMBL29427279 0.77 GAA (0.30)
SCHEMBL17886606 0.72 PDK4 (0.38) L3MBTL1PKMALDH1A1MAPTKMT2A
SCHEMBL22488556 0.71 ESR2 (0.41) MAPTESR2MAPK1SMN1; SMN2
SCHEMBL31078567 0.70 L3MBTL1 (0.35) CYP2D6TSHRL3MBTL1PKMALDH1A1
SCHEMBL21078133 0.70 L3MBTL1 (0.38) CYP2D6TSHRL3MBTL1PKMALDH1A1
SCHEMBL8663120 0.69 F13A1 (0.35) CYP2D6TSHRL3MBTL1PKMALDH1A1
SCHEMBL26064534 0.69 ESR2 (0.44) KMT2AESR2MEN1MAPK1SMN1; SMN2
SCHEMBL3544645 0.69 L3MBTL1 (0.34) CYP2D6TSHRL3MBTL1PKMALDH1A1
SCHEMBL6079220 0.68 L3MBTL1 (0.39) TSHRL3MBTL1PKMALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE CYP2D6 3718/4885TSHR 3540/4885L3MBTL1 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.